PRKCD and plasma cell myeloma: Our data show that eriodictyol can sensitize U266 multiple myeloma cells to plasma concentration of EGCG (IC50 of 6.6 μM in the presence of eriodictyol) by enhancing the 67LR-mediated Akt/eNOS/PKCδ/ASM signalling pathway without deleterious effects on normal cells.